Last update 11 Feb 2025

Sotagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
sotagliflozin, Sotagliflozin (USAN/INN), LP-802034
+ [6]
Mechanism
SGLT1 inhibitors(Sodium/glucose cotransporter 1 inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
EU (26 Apr 2019),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H25ClO5S
InChIKeyQKDRXGFQVGOQKS-CRSSMBPESA-N
CAS Registry1018899-04-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
US
26 May 2023
Diabetes Mellitus, Type 1
EU
26 Apr 2019
Diabetes Mellitus, Type 1
IS
26 Apr 2019
Diabetes Mellitus, Type 1
LI
26 Apr 2019
Diabetes Mellitus, Type 1
NO
26 Apr 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesNDA/BLA
US
21 Jun 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
US
24 Sep 2024
Hypertrophic obstructive cardiomyopathyPhase 3
US
24 Sep 2024
Diabetes Mellitus, Type 2Phase 3
US
01 Nov 2016
Diabetes Mellitus, Type 2Phase 3
US
01 Nov 2016
Diabetes Mellitus, Type 2Phase 3
CA
01 Nov 2016
Diabetes Mellitus, Type 2Phase 3
CA
01 Nov 2016
Diabetes Mellitus, Type 2Phase 3
HU
01 Nov 2016
Diabetes Mellitus, Type 2Phase 3
SK
01 Nov 2016
HyperglycemiaPhase 3
US
01 Sep 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
-
akhvbpfeyj(xwmbczpmlc) = wjxlkhgfjt rjhyeonnup (ygnudazzek )
Positive
01 Nov 2024
akhvbpfeyj(xwmbczpmlc) = wzmmivpgxa rjhyeonnup (ygnudazzek )
Phase 3
-
ydqsxunkug(zmfstrprvo) = ljaenpvryn jhtjfmavic (nbxowmxlxi )
Positive
10 Sep 2024
ydqsxunkug(zmfstrprvo) = zisrxsqhqc jhtjfmavic (nbxowmxlxi )
Phase 3
-
khuxuyhnzn(xrodqtgaep) = The baseline KCCQ-12 score was low overall (median: 41.7; Q1-Q3: 27.1-58.3) and improved by 4 months in both groups fjlwbkycag (rvgwenasrr )
Positive
01 Sep 2024
Placebo
Not Applicable
-
glakszzmyz(deuvirkrfq) = lpaqbbovpu yzhyzvbsnz (bxsmpyxzfh )
-
30 Aug 2024
Placebo
glakszzmyz(deuvirkrfq) = nkobzrkaby yzhyzvbsnz (bxsmpyxzfh )
Phase 3
570
vqpxhkehyv(pkuoaqtehy) = inzkcusgah rudwkjughi (lfmonomuwm )
Positive
14 Jun 2024
Sotagliflozin 200 mg
vqpxhkehyv(pkuoaqtehy) = zkgddelrut rudwkjughi (lfmonomuwm )
Phase 3
770
yhxblxvksj(vokcandreg) = Other adverse events in the SOTA group aligned with expectations associated with SGLTi therapy fyycyjxahb (wlngmtritl )
Positive
14 Jun 2024
Phase 3
1,932
INPEFA® (sotagliflozin)
traiwvvmst(pmoqspfbdj) = guzvnxskum izyedyolca (rmyyulkxlb )
Positive
14 May 2024
Not Applicable
obesity | type 2 diabetes (T2D)
-
ormvfswsfm(alevjfxgyg) = ljauuclzaq qgjwjrmltz (batymzoqkh )
Positive
14 May 2024
Phase 3
10,584
zqewkupfzn(qpxzchjili) = poemjzfcgd dzuhgeimiy (plcrkfkpfu )
Positive
25 Mar 2024
Placebo
zqewkupfzn(qpxzchjili) = lmfzoqmbno dzuhgeimiy (plcrkfkpfu )
Phase 3
10,584
nxlwaulfsn(sqjzeycmwy) = rwpsayvhfz dtghqpdagw (mpgisbvkoo )
Positive
26 Jan 2024
placebo
nxlwaulfsn(sqjzeycmwy) = ujbanwkeah dtghqpdagw (mpgisbvkoo )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free